Jared Baeten

1 week ago | contagionlive.com | Sophia Abene |Jared Baeten

Gilead Sciences, Inc announced today that the US Food and Drug Administration (FDA) has granted approval for lenacapavir, the company’s first-in-class, long-acting HIV-1 capsid inhibitor, for use as a twice-yearly pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Nov 11, 2024 | contagionlive.com | Sophia Abene |Jared Baeten

Gilead Sciences and Merck have announced promising Phase 2 clinical trial results for an investigational weekly oral combination regimen of islatravir and lenacapavir, demonstrating sustained viral suppression in adults living with HIV after 48 weeks. This innovative regimen could become the first once-weekly oral treatment for HIV.

Oct 16, 2024 | contagionlive.com | Sophia Abene |Jared Baeten

Gilead's Phase 1a clinical trial evaluated the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of GS-1720, a novel oral long-acting integrase strand transfer inhibitor (INSTI), in healthy adults without HIV-1. Presented at this year's IDWeek, the study demonstrated that GS-1720 has the potential to be a transformative treatment option for people living with HIV, with primary endpoints indicating favorable pharmacokinetic properties.

Oct 7, 2024 | contagionlive.com | John Parkinson |Jared Baeten

Gilead announced that its twice-yearly injectable HIV capsid inhibitor, lenacapavir (Sunlenca), was found to be safe and tolerable for participants in a PrEP study.1Findings from the ongoing PURPOSE 2 trial demonstrated no significant or new safety concerns identified, and lenacapavir was generally well-tolerated.